113465-94-4 Usage
General Description
1H-Pyrazole-3-acetic acid, 5-methyl-, methyl ester is a chemical compound with the molecular formula C8H10N2O2. It falls under the class of organic compounds known as pyrazoles, which are compounds containing a pyrazole ring, a five-membered aromatic ring with two nitrogen atoms and three carbon atoms. The 5-methyl- denotes the presence of a methyl group attached to the fifth carbon in the pyrazole structure, and the 'methyl ester' denotes an ester functional group (-COOCH3). Ester forms of acids are often used in chemistry for their stabilities and better reactivity compared to their parent acids. As a specific compound, 1H-Pyrazole-3-acetic acid, 5-methyl-, methyl ester's particular properties, usage, and safety measures can vary depending on the context of its application in various scientific and industrial fields.
Check Digit Verification of cas no
The CAS Registry Mumber 113465-94-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,1,3,4,6 and 5 respectively; the second part has 2 digits, 9 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 113465-94:
(8*1)+(7*1)+(6*3)+(5*4)+(4*6)+(3*5)+(2*9)+(1*4)=114
114 % 10 = 4
So 113465-94-4 is a valid CAS Registry Number.
113465-94-4Relevant articles and documents
Pyridine, Pyrimidine and Pyrazine Derivatives as Cxcr3 Receptor Modulators
-
Page/Page column 21, (2009/02/11)
The invention encompasses compounds of Formula I or pharmaceutically acceptable salts thereof, which are modulators of the CXCR3 chemokine receptor function useful for the treatment or prevention of pathogenic inflammatory processes, autoimmune diseases o
2-ARYLTHIAZOLE DERIVATIVES AS CXCR3 RECEPTOR MODULATORS
-
Page/Page column 100-101, (2010/11/28)
The invention encompasses compounds of Formula I or pharmaceutically acceptable salts thereof, which are modulators of the CXCR3 chemokine receptor function useful for the treatment or prevention of pathogenic inflammatory processes, autoimmune diseases or graft rejection processes. Methods of use and pharmaceutical compositions are also encompassed.
